-
Mashup Score: 2SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL? - 1 month(s) ago
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Polatuzumab vedotin in combination with venetoclax and rituximab for patients with R/R DLBCL - 1 month(s) ago
Here, we summarize results from a phase Ib/II trial assessing the safety and efficacy of polatuzumab vedotin in combination with rituximab and lenalidomide in patients with R/R DLBCL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13GLOW trial: A 4-year update on fixed-duration ibrutinib + venetoclax in previously untreated CLL - 1 month(s) ago
Here, we summarize the 4-year follow-up data from the phase III GLOW trial investigating fixed duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in previously untreated chronic lymphocytic leukemia published by Niemann, et al.1 in The Lancet Oncology.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9TARMAC trial: Time-limited ibrutinib plus CAR T-cell therapy for the treatment of R/R MCL - 1 month(s) ago
Here, we summarize the results of the phase II TARMAC trial, published by Minson et al.1 in Blood, of the combination of time-limited ibrutinib and CTL019 CAR T-cells in patients with R/R MCL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
On March 14, 2024, the U.S. FDA approved lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy, for the treatment of adult patients with R/R CLL/SLL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Venetoclax for del(17p) chronic lymphocytic leukemia: Long-term follow-up data from the M13-982 trial - 2 month(s) ago
Here, we summarize the 6-year follow-up and subgroup analyses from the M13-982 trial that assessed venetoclax monotherapy in patients aged ≥18 years with R/R or previously untreated del(17p) CLL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
We summarize a presentation of real-world data on tocilizumab for the management of CAR T-cell-associated cytokine release syndrome shared by Delaney at the EBMT-EHA 6th CAR T-cell meeting.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Zanubrutinib plus obinutuzumab receives accelerated U.S. FDA approval for adult patients with R/R FL - 2 month(s) ago
Following positive response data from the phase II ROSEWOOD study, zanubrutinib plus obinutuzumab receives accelerated U.S. FDA approval for the treatment of adult patients with R/R follicular lymphoma.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Here, we summarize an article on the outcomes of subsequent therapies after 2L axi-cel or SOC treatment in patients with R/R LBCL in the ZUMA-7 study published by Ghobadi et al. in Blood Advances.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
📽️ The Lymphoma Hub was pleased to speak to Michael Wang, @MDAndersonNews, Houston, US. We asked, Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL? Click here to see what was said 👉 https://t.co/5nMdtd9mV4 #ASH2023 #leusm #lymsm https://t.co/FV3r9hVC0R